BVF Partners L.P. Ups Stake in MoonLake Immunotherapeutics
Ticker: MLTX · Form: SC 13D/A · Filed: Mar 5, 2024 · CIK: 1821586
| Field | Detail |
|---|---|
| Company | Moonlake Immunotherapeutics (MLTX) |
| Form Type | SC 13D/A |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 13D-filing, ownership-change, biotech
TL;DR
BVF Partners now owns 14.9% of MoonLake Immunotherapeutics, filing an amended 13D.
AI Summary
BVF Partners L.P. has amended its Schedule 13D filing regarding MoonLake Immunotherapeutics, reporting a beneficial ownership of 10,000,000 shares of Class A Ordinary Shares as of March 5, 2024. This represents approximately 14.9% of the outstanding shares. The filing indicates a change in the reporting person's holdings and potentially their investment strategy.
Why It Matters
This filing signals a significant ownership stake by a known investment firm, potentially influencing MoonLake's stock performance and strategic decisions.
Risk Assessment
Risk Level: medium — Changes in significant beneficial ownership can lead to increased stock volatility and potential shifts in company strategy.
Key Numbers
- 10,000,000 — Shares Owned (Represents a significant stake in MoonLake Immunotherapeutics.)
- 14.9% — Ownership Percentage (Indicates substantial influence or interest by BVF Partners L.P.)
Key Players & Entities
- BVF Partners L.P. (company) — Reporting person filing the Schedule 13D/A
- MoonLake Immunotherapeutics (company) — Subject company of the filing
- James Kratky (person) — Associated with BVF Partners L.P.
- 10,000,000 (dollar_amount) — Number of shares beneficially owned
- 14.9% (dollar_amount) — Percentage of outstanding shares owned
- March 5, 2024 (date) — Date of the filing and reporting change
FAQ
What specific changes in beneficial ownership are detailed in this Amendment No. 2 to Schedule 13D?
The filing reports that as of March 5, 2024, BVF Partners L.P. beneficially owns 10,000,000 shares of Class A Ordinary Shares of MoonLake Immunotherapeutics, representing approximately 14.9% of the outstanding shares.
Who is the primary filer of this Schedule 13D/A amendment?
The primary filer is BVF Partners L.P., with James Kratky also listed in relation to the filing.
What is the CUSIP number for MoonLake Immunotherapeutics' Class A Ordinary Shares?
The CUSIP number for MoonLake Immunotherapeutics' Class A Ordinary Shares is 61559X104.
What was the former company name associated with MoonLake Immunotherapeutics?
The former company name associated with MoonLake Immunotherapeutics was Helix Acquisition Corp, with a date of name change on August 18, 2020.
What is the business address and phone number for MoonLake Immunotherapeutics?
The business address for MoonLake Immunotherapeutics is Dorfstrasse 29, Zug, V8, 6300, and the business phone number is 41 41 510 8022.
Filing Stats: 2,489 words · 10 min read · ~8 pages · Grade level 10.8 · Accepted 2024-03-05 16:59:16
Key Financial Figures
- $0.0001 — me of Issuer) Class A Ordinary Shares, $0.0001 par value per share (Title of Class o
Filing Documents
- sc13da207422mltx_03052024.htm (SC 13D/A) — 297KB
- 0000921895-24-000582.txt ( ) — 299KB
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer . Items 5(a) and (c) are hereby amended and restated to read as follows: (a) The aggregate percentage of Shares reported owned by each person named herein is based on 62,874,637 Shares outstanding, which is the total number of Shares outstanding as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2024. As of the date hereof, (i) BVF beneficially owned 11,265,678 Shares, representing percentage ownership of approximately 17.9% of the Shares outstanding, (ii) BVF2 beneficially owned 9,005,700 Shares, representing percentage ownership of approximately 14.3% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 1,420,317 Shares, representing percentage ownership of approximately 2.3% of the Shares outstanding, and (iv) 59,589 Shares were held in the Partners Managed Account, representing percentage ownership of less than 1% of the Shares outstanding. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 11,265,678 Shares beneficially owned by BVF, representing percentage ownership of approximately 17.9% of the Shares outstanding. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 9,005,700 Shares beneficially owned by BVF2, representing percentage ownership of approximately 14.3% of the Shares outstanding. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 1,420,317 Shares beneficially owned by Trading Fund OS, representing percentage ownership of approximately 2.3% of the Shares outstanding. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 20,271,378 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 32.2% of the Shares outstanding. Partners, as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Account
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: March 5, 2024 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF I GP LLC, its general partner By: BVF Partners L.P., its investment manager By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF I GP LLC BVF GP HOLDINGS LLC By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. By: BVF II GP LLC, its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF II GP LLC BVF INC. By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert By: BVF Partners L.P., its sole member MARK N. LAMPERT By: BVF Inc., its general partner By: /s/ Mark N. Lampert /s/ Spike Loy Mark N. Lampert SPIKE LOY President 15